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In 1898, Tigerstedt and Bergman discovered that a cortical extract
of rabbit kidney has vasopressive properties when injected intra-
venously.1 This is how a long and beautiful story started, leading
to characterization of the renin–angiotensin–aldosterone system
and to elucidation of its physiological and pathophysiological func-
tions.2 –5 Presently, blockers of this system play a prominent role in
the treatment of arterial hypertension, heart failure, diabetes, and
nephropathy.6,7
Considerable progress was made when it became possible to
assay renin in blood.2 –5 The regulation of renin secretion is
complex, with a key role played by sodium balance. In man,
the blood concentration of renin is inversely related to oral
sodium intake. This relationship was taken into account in two
studies seeking to evaluate cardiovascular risk in hypertensive
patients, using stratification according to plasma renin activity
level (low, normal, and high). The first study, by H.R Brunner
and colleagues, showed an association of abnormally high renin
secretion and increased risk of stroke or myocardial infarction.8
Subsequently, these results were challenged, and two decades
elapsed before their corroboration by Alderman and colleagues.9
These authors reported that subjects with high plasma renin
were at increased risk of cardiovascular events, notably myocar-
dial infarction, results that were more convincing than the initial
observations, due to a patient population (1717 hypertensive
patients, as compared with 219 in the initial study). Nevertheless,
this new result did not end the controversy surrounding the po-
tentially deleterious impact of renin on cardiovascular risk.10
Therefore, we must ponder on the best option for antihyperten-
sive therapy. Is there any advantage in blocking the renin–
angiotensin system of all patients, or should we target only
those in whom renin is most likely to be elevated, based on
criteria such as age? Should we be wary of stimulating the
renin–angiotensin system if we prescribe a diuretic alone
without a blocker of this system?11
The recent study by de Boer and colleagues provides the best
evidence to date that plasma renin concentration has a prognostic
value for the occurrence of cardiovascular events, independent of
blood pressure level.12 Several features of this work are worth
mentioning. (i) The investigated cohort comprises a large number
of adults (n ¼ 6228), all living in the same city and having responded
favourably to a written invitation for participation sent to all inhabi-
tants of this city. The results are therefore likely to be representa-
tive for a general urban western population. (ii) Subjects were
followed for an extensive period, on average  10 years. (iii) Enrol-
ment was not restricted to hypertensive subjects, but was also open
to normotensive subjects who had not incurred any cardiovascular
complication such as stroke at the time of inclusion. (iv) When the
cohort was subdivided according to quintiles of renin levels, the
subgroups did not differ with respect to blood pressure and 24 h
sodium excretion, making it possible to study the association of
renin level with cardiovascular outcome independently of blood
pressure and dietary sodium intake.
What do the results tell us? That high circulating renin levels are
associated with increased cardiovascular morbidity and mortality,
even after correcting for traditional risk factors.
From a clinical viewpoint, this observation is all the more rele-
vant since it concerns a population of both hyper- and normoten-
sive subjects. In this study, plasma renin levels were measured;
these are known to correlate with plasma renin activity. Increased
renin secretion is expected to augment the circulating concentra-
tions of angiotensin II and perhaps also the production of angioten-
sin II at the tissue level.13 It is to be regretted that the authors have
not taken advantage of their enormous data bank also to assay
active renin and prorenin, the latter being potentially involved in
the tissue production of angiotensin II.14,15 Wherever it is
formed, this peptide plays a crucial role in the pathogenesis of vas-
cular disease, in particular by inducing oxidative stress, which in
turn triggers an inflammatory response.16
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The treated hypertensive participants (n ¼ 843) have not
been taken into account in the primary analysis, but have
been used for a subanalysis. In these patients, renin levels had
no link to cardiovascular risk. Perhaps there were too few of
them. The most likely explanation relates to the diverse
effects of various antihypertensive agents on renin secretion.
Whereas diuretics stimulate the renin– angiotensin system, beta-
blockers—if devoid of intrinsic sympathomimetic activity—act in
the opposite direction. Dihydropyridine-type calcium antagonists
tend to increase renin secretion, but most often only transiently
at the onset of treatment. Regarding angiotensin-
converting enzyme inhibitors and antagonists of angiotensin II,
they induce hyper-reninaemia, due to the inactivation of the
negative feedback control normally exerted on renin secretion
by angiotensin II. Here, a few thoughts are in order. Can mono-
therapy with diuretics be truly beneficial, considering that such
therapy stimulates the renin–angiotensin system? If optimal pre-
vention of cardiovascular complications is our goal, should we
not systematically associate an antagonist of the renin–angiotensin
system with a diuretic? Unfortunately, no answer to these ques-
tions is yet available. At the very most, we know that concomi-
tant blockade of the renin–angiotensin system attenuates the
metabolic effects of diuretics, which should be favourable in the
long term.
The main message of the study by de Boer et al. is to confirm the
association of high renin levels and increased cardiovascular risk.
Based on this fact, some might propose the systematic assay of
plasma renin as an additional tool for refining the stratification of
cardiovascular risk. More practically, prescribing a blocker of the
renin–angiotensin system could be considered in every patient
with either hypertension, heart failure, or kidney disease, without
determining the renin status. Such an approach would be expected
to be of benefit not only to patients with high renin levels, but also
to those with normal or low renin levels.
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